Ajooni Biotech has closed its trading window for all officers and designated employees, including directors, effective from Wednesday, July 01, 2026. The closure is implemented to ensure compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as the company prepares to declare its unaudited financial results for the quarter ended June 30, 2026. The restriction prevents insider trading during the sensitive period surrounding financial disclosures.

The decision aligns with the company's code of conduct for the prohibition of insider trading and Circular No. NSE/CML/2019/11 dated April 02, 2019. The trading window will remain closed for all designated personnel until 48 hours after the unaudited financial results for the quarter ended June 30, 2026 are officially announced to the stock exchange. Both the start date and the end date of the closure are inclusive.

Compliance and Regulatory Framework

The closure of the trading window is a standard regulatory procedure mandated by SEBI to maintain market integrity and prevent the misuse of unpublished price-sensitive information (UPSI). By adhering to these regulations, Ajooni Biotech ensures that all market participants have equal access to material information at the time of public disclosure.

The intimation was formally addressed to the National Stock Exchange of India Ltd, confirming the company's adherence to the prescribed timelines and protocols. The communication was authenticated by Swati Vijan, Company Secretary of Ajooni Biotech Limited.

Ajooni Biotech reported a 28.2% increase in net profit to ₹432.19 lakh for the financial year ended March 31, 2026, driven by a significant rise in operational income. Revenue from operations grew 59% to ₹18,237.81 lakh from ₹11,469.19 lakh in the previous year, while total income increased to ₹18,479.62 lakh. The company’s earnings per share (EPS) for the year improved to ₹0.25 on a basic and diluted basis, up from ₹0.20 in FY25.

The Board of Directors approved the audited financial results for FY26 at a meeting held on May 28, 2026. The statutory auditors, Narinder Kumar and Company, issued an unmodified opinion on the financial statements. The audit confirmed that the company has maintained proper internal financial controls over financial reporting, which were operating effectively as of March 31, 2026.

Financial Performance

The company’s total expenses for FY26 rose to ₹17,905.79 lakh, compared to ₹11,243.16 lakh in the prior year, primarily due to higher material costs and other operational expenses. The cost of materials consumed increased to ₹14,805.33 lakh from ₹9,715.42 lakh. Despite the rise in costs, the profit before tax for the year stood at ₹573.83 lakh, up from ₹432.92 lakh in FY25.

For the quarter ended March 31, 2026, Ajooni Biotech posted a net profit of ₹94.72 lakh on revenue from operations of ₹6,062.21 lakh. This compares to a net profit of ₹154.38 lakh and revenue of ₹2,927.44 lakh in the corresponding quarter of the previous year.

Balance Sheet and Cash Flows

The company’s total assets as of March 31, 2026, stood at ₹12,036.51 lakh, an increase from ₹9,505.11 lakh a year earlier. Non-current assets, including property, plant, and equipment, were valued at ₹2,585.57 lakh. Current assets, dominated by inventories worth ₹3,945.51 lakh and trade receivables of ₹1,783.43 lakh, constituted a significant portion of the balance sheet.

Equity share capital remained unchanged at ₹3,444.87 lakh, while other equity increased to ₹5,674.27 lakh from ₹5,363.02 lakh. The company’s cash and cash equivalents decreased to ₹41.90 lakh at the end of FY26 from ₹683.02 lakh in the previous year, as reflected in the cash flow statement.